CN102027003A - 衣原体抗原 - Google Patents

衣原体抗原 Download PDF

Info

Publication number
CN102027003A
CN102027003A CN200880110106XA CN200880110106A CN102027003A CN 102027003 A CN102027003 A CN 102027003A CN 200880110106X A CN200880110106X A CN 200880110106XA CN 200880110106 A CN200880110106 A CN 200880110106A CN 102027003 A CN102027003 A CN 102027003A
Authority
CN
China
Prior art keywords
fragment
sequence
amino acid
polypeptide
aminoacid replacement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880110106XA
Other languages
English (en)
Chinese (zh)
Inventor
达雷恩·E·希金斯
托德·吉拉恩
迈克尔·N·斯塔恩巴赫
纳迪亚·R·罗恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN102027003A publication Critical patent/CN102027003A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880110106XA 2007-08-03 2008-08-01 衣原体抗原 Pending CN102027003A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96321507P 2007-08-03 2007-08-03
US60/963,215 2007-08-03
PCT/US2008/009282 WO2009020553A2 (en) 2007-08-03 2008-08-01 Chlamydia antigens

Publications (1)

Publication Number Publication Date
CN102027003A true CN102027003A (zh) 2011-04-20

Family

ID=40341938

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880110106XA Pending CN102027003A (zh) 2007-08-03 2008-08-01 衣原体抗原

Country Status (7)

Country Link
US (1) US20100260791A1 (enExample)
EP (1) EP2185577A4 (enExample)
JP (1) JP2010535504A (enExample)
CN (1) CN102027003A (enExample)
AU (1) AU2008284352A1 (enExample)
CA (1) CA2695421A1 (enExample)
WO (1) WO2009020553A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093694A (zh) * 2017-07-13 2020-05-01 纳诺碧欧公司 衣原体纳米乳剂疫苗

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
AU2012253359B2 (en) 2011-05-11 2017-06-08 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
TR201809679T4 (tr) * 2012-12-28 2018-07-23 Cellestis Ltd Hücre aracılı bir immün yanıt tahlili.
AU2018240199A1 (en) 2017-03-20 2019-10-17 Genocea Biosciences, Inc. Treatment methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
CN1280619A (zh) * 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60228758D1 (de) * 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
WO2005002619A2 (en) * 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
US8481057B2 (en) * 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111093694A (zh) * 2017-07-13 2020-05-01 纳诺碧欧公司 衣原体纳米乳剂疫苗

Also Published As

Publication number Publication date
EP2185577A4 (en) 2010-09-22
US20100260791A1 (en) 2010-10-14
WO2009020553A3 (en) 2009-04-09
AU2008284352A1 (en) 2009-02-12
AU2008284352A2 (en) 2010-05-27
WO2009020553A2 (en) 2009-02-12
CA2695421A1 (en) 2009-02-12
EP2185577A2 (en) 2010-05-19
JP2010535504A (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
JP6916231B2 (ja) 新生物ワクチン用製剤
US20240156953A1 (en) Human herpesvirus immunotherapy
CN102027003A (zh) 衣原体抗原
JP2025085695A (ja) 既存の微生物免疫を利用した癌処置
CN103945864A (zh) 截短的hiv包膜蛋白(env)、其相关方法和组合物
TWI507413B (zh) 脂質化多抗原表位疫苗
TW202334198A (zh) 用於避免感染與治療遠程新冠肺炎之針對SARS-CoV-2 OMICRON BA.4/BA.5的疫苗組成物
KR102620487B1 (ko) 백신으로 사용하기 위한 엑소좀-앵커링 단백질을 발현하는 뉴클레오티드 서열
CN1639569B (zh) 诱导免疫应答的方法和组合物
JP2022501046A (ja) アルギナーゼ１ポリペプチド
JP2009511452A (ja) Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ
US8637053B2 (en) Chlamydia antigens
JP2004522789A (ja) 乳頭腫ウイルスワクチン
HK40057947A (en) Improved human herpesvirus immunotherapy
JPH01151527A (ja) 細胞毒性ｔ細胞応答の誘発方法
AU2002258614B2 (en) Human papilloma virus immunoreactive peptides
HK40006634A (en) Improved human herpesvirus immunotherapy
EP2331104A2 (en) Method of inducing an anti-viral immune response

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110420